Research
Hormonal
Adipose tissue dysfunction, specifically the release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and free fatty acids from visceral fat, drives insulin resistance and beta-cell dysfunction in obesity.
Fat is not just stored energy; it actively sends inflammatory signals that block your body's ability to use insulin. Reducing visceral fat reduces this inflammation, thereby improving insulin sensitivity.
GoodSupportsHIGH confidence
This chronic inflammatory state is a key factor contributing to the pathogenesis of insulin resistance, which decreases the glucose uptake in muscle, leads to increase glucose production in liver, provokes β-cell dysfunction in pancreas and results in endocrine dysfunction of adipose tissue
Why this rating
Supported by multiple in vivo studies and mechanistic reviews cited.
Source
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Preethi Chandrasekaran et al. · International Journal of Molecular Sciences · 2024
DOI 10.3390/ijms25031882
narrative_reviewCited 393×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is the most significant risk factor for the development and progression of Type 2 Diabetes, with obesity accounting for 44% of diabetes cases globally.Strong
- Moderate and sustained weight loss through combined diet, exercise, and lifestyle modifications improves blood glucose levels, insulin action, and reduces the need for diabetic medications in individuals with obesity and type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →